PLoS ONE (Jan 2020)

Peritumor to tumor apparent diffusion coefficient ratio is associated with biologically more aggressive breast cancer features and correlates with the prognostication tools.

  • Hidemi Okuma,
  • Mazen Sudah,
  • Tiia Kettunen,
  • Anton Niukkanen,
  • Anna Sutela,
  • Amro Masarwah,
  • Veli-Matti Kosma,
  • Päivi Auvinen,
  • Arto Mannermaa,
  • Ritva Vanninen

DOI
https://doi.org/10.1371/journal.pone.0235278
Journal volume & issue
Vol. 15, no. 6
p. e0235278

Abstract

Read online

PurposeThe apparent diffusion coefficient (ADC) is increasingly used to characterize breast cancer. The peritumor/tumor ADC ratio is suggested to be a reliable and generally applicable index. However, its overall prognostication value remains unclear. We aimed to evaluate the associations between the peritumor/tumor ADC ratio and histopathological biomarkers and published prognostic tools in patients with invasive breast cancer.Materials and methodsThis prospective study included 88 lesions (five bilateral) in 83 patients with primary invasive breast cancer who underwent preoperative 3.0-T magnetic resonance imaging. The lowest intratumoral mean ADC value on the slice with the largest tumor cross-sectional area was designated the tumor ADC, and the highest mean ADC value on the peritumoral breast parenchymal tissue adjacent to the tumor border was designated the peritumor ADC. The peritumor/tumor ADC ratio was then calculated. The tumor and peritumor ADC values and peritumor/tumor ADC ratios were compared with histopathological parameters using an unpaired t test, and their correlations with published prognostic tools were evaluated with Pearson's correlation coefficient.ResultsThe peritumor/tumor ADC ratio was significantly associated with tumor size (pConclusionThe peritumor/tumor ADC ratio was correlated with histopathological biomarkers in patients with invasive breast cancer, showed significant correlations with published prognostic indexes, and may provide an easily applicable imaging index for the preoperative prognostic evaluation of breast cancer.